XML 59 R45.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaborations, Licensing Agreements and other Agreements - Additional Information (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2024 | May 31, 2020 | Mar. 31, 2024 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023 | Jan. 31, 2024 | Aug. 31, 2023 | May 31, 2023 | Mar. 31, 2023 | Oct. 07, 2022
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | $ 97,203 | $ 55,424 |  |  |  |  |
Upfront license fee | $ 1,100 |  |  |  | 1,100 |  |  |  |  |  |
License Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Obligation to be paid | 2,000 |  |  |  | $ 2,000 |  |  |  |  |  |
Payment term |  |  |  |  | 3 years |  |  |  |  |  |
License maintenance fee |  | $ 33 |  |  | $ 10 |  |  |  |  |  |
Total milestone payments |  |  |  |  | 21,000 |  |  |  |  |  |
Amounts due to agreement | 0 |  |  |  | 0 |  |  |  |  |  |
Sponsored Research Agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Obligation to be paid | 12,560 |  |  |  | 12,560 |  |  |  |  |  |
Master Translational Research Services Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 3,250 | 3,786 |  |  |  |  |
Remaining research and development expense to be incurred |  |  |  |  | 643 |  |  |  |  |  |
Oxford Biomedica |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Obligation to be paid | 1,100 |  |  |  | 1,100 |  |  | $ 5,000 |  |  |
Research and development expense | 9,000 |  |  |  |  |  |  |  |  |  |
Expenses |  |  |  |  | 3,500 | $ 1,500 |  |  |  |  |
Upfront license fee |  |  |  |  |  |  |  |  | $ 500 |  |
IASO Biotherapeutics |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront license fee | $ 162,000 |  |  |  | 162,000 |  |  |  |  |  | $ 2,500
Milestone payment |  |  | $ 1,500 |  | 1,000 |  |  |  |  |  |
Autolus Holdings Member |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  |  | $ 100 |  |  | $ 1,200 |
Autolus Holdings Member | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 15,000 |  |  |  |  |  |
Autolus Holdings Member | Maximum | License and Service [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | $ 12,000 |  |  |  |  |  |
Subsequent Event [Member] | Master Translational Research Services Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | $ 3,000 |  |  |  |  |  |  |

X
- Definition Collaborations licensing agreements and other agreements. + References No definition available. + Details
Name: | caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems
Namespace Prefix: | caba_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement payments due. + References No definition available. + Details
Name: | caba_CollaborativeAgreementPaymentsDue
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License maintenance fee. + References No definition available. + Details
Name: | caba_LicenseMaintenanceFee
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment + References No definition available. + Details
Name: | caba_MilestonePayment
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | caba_MilestonePayments
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of obligation, term. + References No definition available. + Details
Name: | caba_PaymentOfObligationTerm
Namespace Prefix: | caba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining research and development expense to be incurred. + References No definition available. + Details
Name: | caba_RemainingResearchAndDevelopmentExpenseToBeIncurred
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment + References No definition available. + Details
Name: | caba_UpfrontPayment
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |